drugset
drugset / Trial / NCT00824421

A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

NCT00824421 ↗

Phase 2 Completed 195 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a 96 week study to determine if UK- 453,061 in combination with Truvada is as efficacious, safe and tolerable as efavirenz in combination with Truvada in HIV-1 infected patients who have not been previously treated with antiretroviral drugs.

Timeline

Start
2009-02
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified 600 mg Oral
Subject Lersivirine Small molecule 500 mg Oral
Subject Lersivirine Small molecule 750 mg Oral
Background Tenofovir disoproxil fumarate Small molecule 300 mg Oral
Background emtricitabine Other / unclassified 200 mg Oral

Indications

No indication recorded.